London
Roots Analysis has announced the
addition of “Live Biotherapeutic Products and Microbiome Contract
Manufacturing Market
Manufacturing live
biotherapeutic products is both technically challenging and financially
demanding; as a result, innovator firms are becoming increasingly reliant on
contract service providers to access specialized facilities and optimize
overall costs.
To
order this 300+ page report, which features 140+ figures and 125+ tables,
please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
Key Market Insights
Over
25 players claim to provide microbiome-based live biotherapeutics contract manufacturing
More than 80% of the companies
engaged in this domain are mid-sized and large firms; examples of firms established in 2019 include Arranta Bio and BacThera
(a Lonza and Chr. Hansen joint venture). Further, nearly 50% of the CMOs
have established the necessary expertise for handling both anaerobic and
aerobic strains.
35+
manufacturing facilities focused on live biotherapeutics have been established worldwide
Majority
(~55%) of the manufacturing facilities are located in Europe, followed by North America. Prominent
manufacturing hubs in the Europe include (in decreasing order of number of manufacturing
facilities)
Approximately
88% of the total installed capacity is dedicated to commercial scale
manufacturing
Whereas, rest (~10%) of the capacity is being used for preclinical / clinical
scale manufacturing of microbiome products. In addition, over 60% of the total
current global, installed manufacturing capacity is installed in Europe.
Over
170 registered clinical trials involved the use of microbiome-based live
biotherapeutics
Majority
of these studies are being conducted at various hospitals / centers across the
US. Examples of leading non-industry players include (in decreasing order of
number of trials) University of California, National Institute of Allergy
and Infectious Diseases, Radboud University, and The University of Texas Health
Science Center.
The global clinical demand
for microbiome-based live biotherapeutic products is anticipated to grow at a CAGR of 23%,
between 2020 and 2030
By
2030, over 31,000 patients are estimated to be enrolled in the clinical trials
involving the use of microbiome-based live biotherapeutics. Industry players
are anticipated to contribute majority (over 60%) of the demand in the
short-term as well as long-term.
Several
big pharma players are actively engaged in the microbiome live biotherapeutics
domain
In
fact, leading pharmaceutical companies have partnered with smaller business
entities to develop manufacturing capabilities related to microbiome-based
therapies / diagnostics. Examples of such small ventures with players with
in-house capability include (in alphabetical order) Assembly
Biosciences, Enterome Bioscience, Finch Therapeutics and NuBiyota.
By 2030, North America and Europe are anticipated to
capture over 85% of the market opportunity
In
terms of type of product manufactured, APIs currently represent the highest
share (58%); this trend is unlikely to change in the foreseen future.
To request a sample
copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/306/request-sample.html
Key
Questions Answered
§ Who
are the leading CMOs offering microbiome contract manufacturing services,
across the world?
§
§ What
is the annual clinical demand for microbiome-based live biotherapeutic products?
§ What is the current, installed contract
manufacturing capacity for live biotherapeutics?
§ What
are the key factors influencing the make (manufacture in-house) versus
buy (outsource) decision in this field?
§ What
are the various initiatives undertaken by big pharma players in this domain?
§ What
percentage of live biotherapeutics manufacturing
operations are outsourced to service providers?
§ How
is the current and future market opportunity likely to be distributed across
key market segments?
§
The USD 300 million (by 2030) financial opportunity
within the microbiome contract manufacturing market has been analysed across
the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
The report features
inputs from eminent industry stakeholders, according to whom the microbiome
therapeutics contract manufacturing services market is likely to witness substantial
growth in the foreseen future. The report includes detailed transcripts of
discussions held with the following experts:
§
§
§
§
§
§
§
§
The
research covers detailed profiles brief profiles of several companies (including
those listed below); each profile features an overview of the company, its
financial information (if available),
microbiome-related service portfolio, facilities dedicated to microbiome
manufacturing, and an informed future outlook.
§
§
§
§
§
§
§
§
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
2.
3.
Contact:
Gaurav Chaudhary
+1
(415) 800 3415
+44
(122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
